

Why should you
**CONSIDER
IMPLEMENTING
A QUALITY
INITIATIVE**
for patients with
MPNs?

Quality initiatives can help oncology practices

- Continually improve care for patients^{1,2}
- Maintain accreditation from organizations such as ACHC, ASCO, URAC®, and The Joint Commission

Multidisciplinary engagement is key to successful implementation of a quality initiative.

Enlist the involvement of physicians, advanced practice providers, nurses, pharmacists, residents and fellows in your practice.

3 STEPS IN THE QUALITY INITIATIVE PROCESS

1 Plan

- Utilize data to understand patient populations that could benefit from a quality initiative (eg, EHRs)
- Identify and partner with physician, advanced practice provider, nurse, and pharmacist champions



2 Implement

- Develop and follow processes
- Check in with teammates to maintain momentum for the initiative



3 Track

- Document the steps taken and the progress made for each patient
- Capture results, share success stories, and identify opportunities for improvement
- Schedule regular check-ins or touchpoints to share learnings and sustain momentum on an ongoing basis



Identify, empower, and secure support from inter-departmental champions who care for patients directly or help navigate their care.

Learn more at MPNQuality.com

How can you
**MAKE A
DIFFERENCE
WITH QUALITY
INITIATIVES**
for patients with
MPNs?

Your patients with MPNs may benefit from disease-specific quality initiatives.

Both the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and European LeukemiaNet recommend ongoing clinical assessments to help inform decision-making for patients with MPNs.^{1,2}

This assessment, in turn, can provide the foundation for specific quality initiatives that can help improve both delivery of care and operational efficiencies.

POTENTIAL MPN QUALITY INITIATIVES

Assure blood counts are managed within target ranges

Routinely assess and manage:

- Elevated Hct $\geq 45\%$ and elevated WBC counts $>11 \times 10^9/L$ in patients with PV
- Anemia and thrombocytopenia in patients with MF



Assess and manage disease-related symptoms

Implement formal symptom assessment protocols, and monitor all patients with MPNs for burdensome disease-related symptoms, such as fatigue, excessive day or night sweats, and/or itchy skin



Monitor and manage the spleen

Assure spleen size is documented at diagnosis for all patients with MPNs, and monitor for new or increasing splenomegaly



Optimize dosing to achieve therapeutic goals

Implement protocols to record each response to dose adjustments (lab values, symptoms, phlebotomy frequency, and adverse events) for all patients with MPNs



A review of EHRs is an effective way to identify opportunities to implement these strategies in your practice.

Learn more at MPNQuality.com

EHR, electronic health record; Hct, hematocrit; MF, myelofibrosis; MPN, myeloproliferative neoplasm; NCCN, National Comprehensive Cancer Network; PV, polycythemia vera; WBC, white blood cell.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.2.2021. © National Comprehensive Cancer Network, Inc 2021. All rights reserved. Accessed August 18, 2021. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Barbui T et al. *Leukemia*. 2018;32(5):1057-1069.



Incyte Corporation, 1801 Augustine Cut-off, Wilmington, DE 19803
www.incyte.com
© 2021, Incyte Corporation. MAT-HEM-02415 09/21